Indian Pharma Q1 FY27: Export Growth Meets Strong Company Results

India’s pharmaceutical sector opened FY27 with mixed but largely positive results across exports, domestic sales, and global markets.

Pharma exports rose 6.8 percent year over year to USD 8.1 billion in Q1 FY27. Several drugmakers also reported higher revenue, stronger margins, or better profits during the quarter.

However, some companies faced margin pressure, regulatory concerns, or weaker profitability despite higher sales. The results also showed growing demand for biosimilars, contract development and manufacturing, APIs, specialty medicines, and new product launches.

From Cipla’s record India sales to Biocon’s fourfold profit jump, the quarter offered several signs of growth. At the same time, Aurobindo Pharma and Supriya Lifescience highlighted the challenges facing companies despite strong revenue performance.

India’s Pharma Exports Rise 6.8 percent to USD 8.1 Billion

India’s pharma exports reached USD 8.1 billion in Q1 FY27, up 6.8 percent from USD 7.58 billion last year.

• Drug formulations and biologicals contributed USD 5.98 billion, accounting for 73.85 percent of total exports.
• Bulk drugs and intermediates increased 13.84 percent to USD 1.36 billion.
• The US remained the largest market, contributing USD 2.5 billion, or 30.89 percent of exports.

Natco Pharma Posts Q1 Results and Plans Fresh Fundraising

Natco Pharma reported its Q1 FY27 performance while its board approved plans to raise up to Rs. 2,000 crore. The fundraising could support future business expansion and strategic opportunities.

• The company reported its quarterly financial performance for the June quarter.
• The board approved a fundraising plan of up to Rs. 2,000 crore.
• Investors also tracked the company’s expansion plans and market opportunities.

Supriya Lifescience Sees Profit Fall Despite Revenue Growth

Supriya Lifescience reported a 31 percent year-over-year decline in net profit to Rs. 24 crore in Q1 FY27. Revenue, however, increased 31 percent to Rs. 189 crore.

• EBITDA fell 8 percent to Rs. 47 crore during the quarter.
• EBITDA margin dropped 1,000 basis points to 25 percent.
• Capacity utilization declined to 70 percent from 74 percent in FY26.

The company also commissioned finished dosage manufacturing capabilities at its Ambernath facility. Validation and registration batches are currently underway.

AstraZeneca Pharma India Reports 30 percent Revenue Growth

AstraZeneca Pharma India reported a 30 percent rise in revenue during Q1 FY27. The result reflected continued demand across its portfolio and stronger business performance.

• Revenue increased 30 percent year over year during the quarter.
• Growth was supported by demand across key therapy areas.
• The company continues to expand its presence in specialty medicines.

Bhavana Agrawal, Chief Financial Officer and Director, AstraZeneca Pharma India, said the company’s first-quarter performance builds on its track record of double-digit growth over the past five years. She added that the company remains focused on investing in opportunities that can support long-term growth and value creation.

Praveen Rao Akkinepally, Country President and Managing Director, AstraZeneca Pharma India, said the company’s performance reflects the strength of its portfolio and its focus on reaching more patients in India with innovative medicines. During the quarter, AstraZeneca received regulatory approval for acalabrutinib in combination with venetoclax, with or without obinutuzumab, for previously untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma.

Aurobindo Pharma Faces USFDA Pressure Despite Strong Q1

Aurobindo Pharma delivered strong Q1 performance, but concerns around its Eugia unit affected investor sentiment. The USFDA has previously classified Eugia facilities under Official Action Indicated status.

• Eugia’s regulatory issues remained a key concern for investors.
• The company continues to work with the USFDA on compliance matters.
• Strong quarterly performance was overshadowed by regulatory uncertainty.

Marksans Pharma Posts Record Q1 Profit as Europe Surges

Marksans Pharma reported record profitability in Q1 FY27, while its UK and Europe business became a major growth driver.

• Revenue rose 35.6 percent year over year to Rs. 840.8 crore.
• EBITDA more than doubled to Rs. 213 crore.
• Profit after tax jumped 173.9 percent to Rs. 159 crore.

UK and Europe revenue increased 74.7 percent to Rs. 356 crore. The company said the region has become an important growth engine.

Tatva Chintan Profit More Than Doubles in Q1

Tatva Chintan reported a sharp improvement in Q1 FY27, with net profit rising 140.3 percent year over year. Revenue also recorded strong growth.

• Net profit increased to Rs. 15.98 crore.
• Revenue rose 42.95 percent to Rs. 167.05 crore.
• EBITDA grew 86 percent to Rs. 32.3 crore.

Its EBITDA margin improved to 19 percent from 15 percent a year earlier.

Cipla Sets New India Sales Record in Q1

Cipla’s One India business delivered its best-ever quarterly performance during Q1 FY27. Global revenue reached Rs. 7,119 crore.

• One India revenue grew 12 percent year over year.
• Chronic medicines accounted for 60.4 percent of the portfolio.
• Branded Prescription revenue increased 15.4 percent.

Respiratory, urology, cardiac, and anti-diabetes medicines supported domestic growth. Three new products also strengthened the Trade Generics portfolio.

Achin Gupta, MD and Global CEO, Cipla., said "We are pleased to share that we continue to make considerable progress across our focused markets. In Q1FY27, we delivered global revenues of Rs. 7,119 crore.”

Indegene Revenue Jumps 39.7 percent as Client Base Expands

Indegene reported operating revenue of Rs. 1,063 crore in Q1 FY27. Revenue increased 39.7 percent year over year, supported by new client additions.

• Active clients increased to 105 after 35 new additions.
• Customers generating more than USD 10 million rose from two to 12.
• EBITDA increased 16.9 percent to Rs. 179 crore.

Net profit remained almost flat at Rs. 116 crore. EBITDA margin declined by 330 basis points during the quarter.

Also Read: AI in Drug Discovery and Development: From Lab to Commercial Market

RPG Life Sciences Gains From Domestic Formulations and APIs

RPG Life Sciences reported a 15.8 percent increase in operating revenue to Rs. 195.7 crore. Domestic formulations remained the main growth driver.

• Domestic formulations revenue increased 14.8 percent.
• International sales grew 7.7 percent.
• Naprosyn sales increased 16 percent.

The company’s API unit also resumed operations during Q1. Management expects API operations to support future growth.

In Q1, the company's API unit resumed operations and recorded a YoY  "Going forward, we remain focused on strengthening our international presence and scaling up our API operations that can drive the next wave of growth of us," said Ashok Nair, MD, RPG Life Sciences.

New Launches Help Alembic Pharma Lift Q1 Profit

Alembic Pharmaceuticals reported a 12.1 percent increase in consolidated net profit to Rs. 173.07 crore. Revenue rose sharply during the quarter.

• Revenue reached Rs. 2,149.77 crore.
• Net profit increased from Rs. 154.38 crore.
• New product launches supported sales growth.

Higher operating expenses remained a concern, rising to Rs. 1,943.23 crore. However, higher sales helped offset the increase in costs.

Biocon Profit Jumps Fourfold on Biosimilars Growth

Biocon reported a major jump in Q1 FY27 profit, supported by its biosimilars business. Consolidated revenue also increased during the quarter.

• Revenue increased 10 percent to Rs. 4,336 crore.
• Net profit rose to Rs. 141 crore from Rs. 35 crore.
• Biocon Biologics revenue increased 16 percent to Rs. 2,855 crore.

The US launch of denosumab biosimilars added another growth opportunity. The company expects stronger contributions from the product in coming quarters.

"Biocon has entered FY27 with a clear focus on translating our strategic investments into sustainable growth. A favourable policy environment for biosimilars together with our expanded manufacturing capabilities in the US reinforce our confidence in the long-term opportunities across North America, our biggest market," said Kiran Mazumdar-Shaw, Executive Chairperson, Biocon.

Akums Drugs Sees 55 percent Profit Growth as CDMO Leads

Akums Drugs reported a 55.4 percent year-over-year rise in profit to Rs. 101 crore. Its CDMO business remained the main contributor to growth.

• Operating revenue increased 13.9 percent to Rs. 1,167 crore.
• EBITDA rose 35.4 percent to Rs. 175 crore.
• EBITDA margin improved to 15 percent from 12.6 percent.

CDMO revenue increased to Rs. 964 crore from Rs. 813 crore. Higher volumes and improved API prices supported the segment.

Gland Pharma Crosses Rs. 1,800 Crore Revenue Mark

Gland Pharma reported revenue of Rs. 1,800.27 crore in Q1 FY27. Net profit increased 47.1 percent year over year.

• Revenue increased 19.6 percent year over year.
• EBITDA reached Rs. 489.36 crore.
• EBITDA margin improved to around 27.2 percent.

The company continued focusing on sterile injectables, complex products, capacity expansion, and new global product launches.

"Growth was driven by recent product launches from the CDMO portfolio and strong customer demand for our diversified product mix. We continue to strengthen our platform through investments in differentiated technologies and capacity expansions, which position us well for sustainable long-term growth." said Srinivas Sadu, Executive Chairman, Gland Pharma.

Conclusion

Q1 FY27 showed that India’s pharma sector continues to grow across exports, domestic sales, APIs, biosimilars, and CDMO services. Export growth also points to continued demand from global markets. Companies such as Biocon, Marksans, Gland Pharma, Akums, Cipla, and Tatva Chintan reported strong operating numbers.

However, Supriya Lifescience and Indegene showed that revenue growth does not always translate into higher profits. Regulatory issues at Aurobindo Pharma also show that compliance remains critical for companies targeting global markets.

Overall, Q1 FY27 points to steady growth, but margins, regulations, and global market conditions will remain important for the rest of FY27.